ZA200308535B - 1-Oxa-3,9-diaza-spiro[5,5]undecan-2-ones derivatives and its use as antagonist of the neurikinin receptor. - Google Patents
1-Oxa-3,9-diaza-spiro[5,5]undecan-2-ones derivatives and its use as antagonist of the neurikinin receptor. Download PDFInfo
- Publication number
- ZA200308535B ZA200308535B ZA200308535A ZA200308535A ZA200308535B ZA 200308535 B ZA200308535 B ZA 200308535B ZA 200308535 A ZA200308535 A ZA 200308535A ZA 200308535 A ZA200308535 A ZA 200308535A ZA 200308535 B ZA200308535 B ZA 200308535B
- Authority
- ZA
- South Africa
- Prior art keywords
- formula
- compound
- diaza
- spiro
- oxa
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title description 5
- KAXASJWZSSJLPG-UHFFFAOYSA-N 1-oxa-3,9-diazaspiro[5.5]undecan-2-one Chemical class O1C(=O)NCCC11CCNCC1 KAXASJWZSSJLPG-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 106
- 238000000034 method Methods 0.000 claims description 28
- 125000000217 alkyl group Chemical group 0.000 claims description 26
- 150000003839 salts Chemical class 0.000 claims description 19
- 239000001257 hydrogen Substances 0.000 claims description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims description 12
- 125000003545 alkoxy group Chemical group 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- -1 bromo, morpholinyl Chemical group 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 229910052736 halogen Inorganic materials 0.000 claims description 9
- 150000002367 halogens Chemical class 0.000 claims description 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 8
- 229940044551 receptor antagonist Drugs 0.000 claims description 8
- 239000002464 receptor antagonist Substances 0.000 claims description 8
- 102000002002 Neurokinin-1 Receptors Human genes 0.000 claims description 7
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- 125000001072 heteroaryl group Chemical group 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 5
- 229910052740 iodine Inorganic materials 0.000 claims description 4
- FEYUTRZPSFLEST-UHFFFAOYSA-N spiro[5.5]undecan-4-one Chemical compound C1C(=O)CCCC11CCCCC1 FEYUTRZPSFLEST-UHFFFAOYSA-N 0.000 claims description 4
- ZECJUCGRCJUNIL-UHFFFAOYSA-N 9-[3,5-bis(trifluoromethyl)benzoyl]-3-(1-methylpiperidin-4-yl)-5-phenyl-1-oxa-3,9-diazaspiro[5.5]undecan-2-one Chemical compound C1CN(C)CCC1N1C(=O)OC2(CCN(CC2)C(=O)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C(C=2C=CC=CC=2)C1 ZECJUCGRCJUNIL-UHFFFAOYSA-N 0.000 claims description 3
- KOOSRSYKRYWAAS-UHFFFAOYSA-N 9-[3,5-bis(trifluoromethyl)benzoyl]-5-(3,4-dichlorophenyl)-1-oxa-3,9-diazaspiro[5.5]undecan-2-one Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C(=O)N2CCC3(CC2)C(CNC(=O)O3)C=2C=C(Cl)C(Cl)=CC=2)=C1 KOOSRSYKRYWAAS-UHFFFAOYSA-N 0.000 claims description 3
- HGXVVFLYFCJJSU-UHFFFAOYSA-N 9-[3,5-bis(trifluoromethyl)benzoyl]-5-(3,4-difluorophenyl)-1-oxa-3,9-diazaspiro[5.5]undecan-2-one Chemical compound C1=C(F)C(F)=CC=C1C1C2(CCN(CC2)C(=O)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)OC(=O)NC1 HGXVVFLYFCJJSU-UHFFFAOYSA-N 0.000 claims description 3
- SEAFPVXMSCTQLM-UHFFFAOYSA-N 9-[3,5-bis(trifluoromethyl)benzoyl]-5-(3-chlorophenyl)-1-oxa-3,9-diazaspiro[5.5]undecan-2-one Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C(=O)N2CCC3(CC2)C(CNC(=O)O3)C=2C=C(Cl)C=CC=2)=C1 SEAFPVXMSCTQLM-UHFFFAOYSA-N 0.000 claims description 3
- 125000000623 heterocyclic group Chemical group 0.000 claims description 3
- MIGNBVWFGCBAJP-UHFFFAOYSA-N 9-[3,5-bis(trifluoromethyl)benzoyl]-3-(3-hydroxypropyl)-5-phenyl-1-oxa-3,9-diazaspiro[5.5]undecan-2-one Chemical compound C1CN(C(=O)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CCC21OC(=O)N(CCCO)CC2C1=CC=CC=C1 MIGNBVWFGCBAJP-UHFFFAOYSA-N 0.000 claims description 2
- USKRLFGVPFHMNS-UHFFFAOYSA-N 9-[3,5-bis(trifluoromethyl)benzoyl]-3-(3-morpholin-4-ylpropyl)-5-phenyl-1-oxa-3,9-diazaspiro[5.5]undecan-2-one Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C(=O)N2CCC3(CC2)C(CN(CCCN2CCOCC2)C(=O)O3)C=2C=CC=CC=2)=C1 USKRLFGVPFHMNS-UHFFFAOYSA-N 0.000 claims description 2
- YUONGZINJMHEPL-UHFFFAOYSA-N 9-[3,5-bis(trifluoromethyl)benzoyl]-3-[3-(3-hydroxypyrrolidin-1-yl)propyl]-5-phenyl-1-oxa-3,9-diazaspiro[5.5]undecan-2-one Chemical compound C1C(O)CCN1CCCN1C(=O)OC2(CCN(CC2)C(=O)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C(C=2C=CC=CC=2)C1 YUONGZINJMHEPL-UHFFFAOYSA-N 0.000 claims description 2
- JPGGKPOPGYJXRS-UHFFFAOYSA-N 9-[3,5-bis(trifluoromethyl)benzoyl]-5-(2,5-difluorophenyl)-1-oxa-3,9-diazaspiro[5.5]undecan-2-one Chemical compound FC1=CC=C(F)C(C2C3(CCN(CC3)C(=O)C=3C=C(C=C(C=3)C(F)(F)F)C(F)(F)F)OC(=O)NC2)=C1 JPGGKPOPGYJXRS-UHFFFAOYSA-N 0.000 claims description 2
- FDQWYVXLBAATDZ-UHFFFAOYSA-N 9-[3,5-bis(trifluoromethyl)benzoyl]-5-phenyl-3-(3-pyrrolidin-1-ylpropyl)-1-oxa-3,9-diazaspiro[5.5]undecan-2-one Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C(=O)N2CCC3(CC2)C(CN(CCCN2CCCC2)C(=O)O3)C=2C=CC=CC=2)=C1 FDQWYVXLBAATDZ-UHFFFAOYSA-N 0.000 claims description 2
- 125000001188 haloalkyl group Chemical group 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims 4
- 150000002431 hydrogen Chemical group 0.000 claims 3
- RAQBZJISSNCXQK-UHFFFAOYSA-N 2-[9-[3,5-bis(trifluoromethyl)benzoyl]-2-oxo-5-phenyl-1-oxa-3,9-diazaspiro[5.5]undecan-3-yl]-n,n-dimethylacetamide Chemical compound C1CN(C(=O)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CCC21OC(=O)N(CC(=O)N(C)C)CC2C1=CC=CC=C1 RAQBZJISSNCXQK-UHFFFAOYSA-N 0.000 claims 1
- XJXLCXAGRLBBSN-UHFFFAOYSA-N 9-[3,5-bis(trifluoromethyl)benzoyl]-5-(2,3-difluorophenyl)-1-oxa-3,9-diazaspiro[5.5]undecan-2-one Chemical compound FC1=CC=CC(C2C3(CCN(CC3)C(=O)C=3C=C(C=C(C=3)C(F)(F)F)C(F)(F)F)OC(=O)NC2)=C1F XJXLCXAGRLBBSN-UHFFFAOYSA-N 0.000 claims 1
- DWEXTZOKBAVHDQ-UHFFFAOYSA-N FC(C=1C=C(C(=O)N2CCC3(C(C(N(C(O3)=O)C=3C=NC=CC3)C)C3=CC=CC=C3)CC2)C=C(C1)C(F)(F)F)(F)F Chemical compound FC(C=1C=C(C(=O)N2CCC3(C(C(N(C(O3)=O)C=3C=NC=CC3)C)C3=CC=CC=C3)CC2)C=C(C1)C(F)(F)F)(F)F DWEXTZOKBAVHDQ-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- 102100024304 Protachykinin-1 Human genes 0.000 description 17
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- GTIKLPYCSAMPNG-UHFFFAOYSA-N 2-(3-chlorophenyl)acetonitrile Chemical compound ClC1=CC=CC(CC#N)=C1 GTIKLPYCSAMPNG-UHFFFAOYSA-N 0.000 description 10
- 101800003906 Substance P Proteins 0.000 description 9
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 8
- 101000831616 Homo sapiens Protachykinin-1 Proteins 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- ADNPLDHMAVUMIW-CUZNLEPHSA-N substance P Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 ADNPLDHMAVUMIW-CUZNLEPHSA-N 0.000 description 8
- 238000000746 purification Methods 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 239000001828 Gelatine Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 239000002742 neurokinin 1 receptor antagonist Substances 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 229920005862 polyol Polymers 0.000 description 4
- 150000003077 polyols Chemical class 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 102000003141 Tachykinin Human genes 0.000 description 3
- 102000007124 Tachykinin Receptors Human genes 0.000 description 3
- 108010072901 Tachykinin Receptors Proteins 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000008298 dragée Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 108060008037 tachykinin Proteins 0.000 description 3
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- IHNZTQNFPSAXNC-UHFFFAOYSA-N 1-[3,5-bis(trifluoromethyl)benzoyl]piperidin-4-one Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C(=O)N2CCC(=O)CC2)=C1 IHNZTQNFPSAXNC-UHFFFAOYSA-N 0.000 description 2
- LXKNAUOWEJWGTE-UHFFFAOYSA-N 2-(3-methoxyphenyl)acetonitrile Chemical compound COC1=CC=CC(CC#N)=C1 LXKNAUOWEJWGTE-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- BHEPDJNLAFWGHR-UHFFFAOYSA-N [4-[2-amino-1-(3-chlorophenyl)ethyl]-4-hydroxypiperidin-1-yl]-[3,5-bis(trifluoromethyl)phenyl]methanone Chemical compound C1CN(C(=O)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CCC1(O)C(CN)C1=CC=CC(Cl)=C1 BHEPDJNLAFWGHR-UHFFFAOYSA-N 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000013058 crude material Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- SUSQOBVLVYHIEX-UHFFFAOYSA-N phenylacetonitrile Chemical compound N#CCC1=CC=CC=C1 SUSQOBVLVYHIEX-UHFFFAOYSA-N 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 125000004306 triazinyl group Chemical group 0.000 description 2
- KYWIYKKSMDLRDC-UHFFFAOYSA-N undecan-2-one Chemical compound CCCCCCCCCC(C)=O KYWIYKKSMDLRDC-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- WMGVPDQNPUQRND-UHFFFAOYSA-N (2-methylphenyl)acetonitrile Chemical compound CC1=CC=CC=C1CC#N WMGVPDQNPUQRND-UHFFFAOYSA-N 0.000 description 1
- AVFZOVWCLRSYKC-UHFFFAOYSA-N 1-methylpyrrolidine Chemical compound CN1CCCC1 AVFZOVWCLRSYKC-UHFFFAOYSA-N 0.000 description 1
- IYRCHGRRMKOSHW-UHFFFAOYSA-N 2-(2,3-difluorophenyl)acetonitrile Chemical compound FC1=CC=CC(CC#N)=C1F IYRCHGRRMKOSHW-UHFFFAOYSA-N 0.000 description 1
- UIMMFRUOZOWROM-UHFFFAOYSA-N 2-(2,5-difluorophenyl)acetonitrile Chemical compound FC1=CC=C(F)C(CC#N)=C1 UIMMFRUOZOWROM-UHFFFAOYSA-N 0.000 description 1
- MRDUURPIPLIGQX-UHFFFAOYSA-N 2-(2-chlorophenyl)acetonitrile Chemical compound ClC1=CC=CC=C1CC#N MRDUURPIPLIGQX-UHFFFAOYSA-N 0.000 description 1
- QWZNCAFWRZZJMA-UHFFFAOYSA-N 2-(3,4-dichlorophenyl)acetonitrile Chemical compound ClC1=CC=C(CC#N)C=C1Cl QWZNCAFWRZZJMA-UHFFFAOYSA-N 0.000 description 1
- GNPYERUNJMDEFQ-UHFFFAOYSA-N 2-(3,4-difluorophenyl)acetonitrile Chemical compound FC1=CC=C(CC#N)C=C1F GNPYERUNJMDEFQ-UHFFFAOYSA-N 0.000 description 1
- XNSHCUIBMZSUGL-UHFFFAOYSA-N 2-(3,4-dimethylphenyl)acetonitrile Chemical compound CC1=CC=C(CC#N)C=C1C XNSHCUIBMZSUGL-UHFFFAOYSA-N 0.000 description 1
- 125000003852 3-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(Cl)=C1[H])C([H])([H])* 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- UZUMYZSWGLGNIQ-UHFFFAOYSA-N 9-[3,5-bis(trifluoromethyl)benzoyl]-3-(2-hydroxyethyl)-5-phenyl-1-oxa-3,9-diazaspiro[5.5]undecan-2-one Chemical compound C1CN(C(=O)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CCC21OC(=O)N(CCO)CC2C1=CC=CC=C1 UZUMYZSWGLGNIQ-UHFFFAOYSA-N 0.000 description 1
- LSBVDIUKHIHORU-UHFFFAOYSA-N 9-[3,5-bis(trifluoromethyl)benzoyl]-3-(4,6-dimethoxy-1,3,5-triazin-2-yl)-5-phenyl-1-oxa-3,9-diazaspiro[5.5]undecan-2-one Chemical compound COC1=NC(OC)=NC(N2C(OC3(CCN(CC3)C(=O)C=3C=C(C=C(C=3)C(F)(F)F)C(F)(F)F)C(C=3C=CC=CC=3)C2)=O)=N1 LSBVDIUKHIHORU-UHFFFAOYSA-N 0.000 description 1
- PAWQNUMQYJHIJB-UHFFFAOYSA-N 9-[3,5-bis(trifluoromethyl)benzoyl]-3-[2-(dimethylamino)ethyl]-5-phenyl-1-oxa-3,9-diazaspiro[5.5]undecan-2-one Chemical compound C1CN(C(=O)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CCC21OC(=O)N(CCN(C)C)CC2C1=CC=CC=C1 PAWQNUMQYJHIJB-UHFFFAOYSA-N 0.000 description 1
- DTUXZRLCQJLUGT-UHFFFAOYSA-N 9-[3,5-bis(trifluoromethyl)benzoyl]-5-(2-chlorophenyl)-1-oxa-3,9-diazaspiro[5.5]undecan-2-one Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C(=O)N2CCC3(CC2)C(CNC(=O)O3)C=2C(=CC=CC=2)Cl)=C1 DTUXZRLCQJLUGT-UHFFFAOYSA-N 0.000 description 1
- FHSSJNHSAYDJHV-UHFFFAOYSA-N 9-[3,5-bis(trifluoromethyl)benzoyl]-5-(3-methoxyphenyl)-1-oxa-3,9-diazaspiro[5.5]undecan-2-one Chemical compound COC1=CC=CC(C2C3(CCN(CC3)C(=O)C=3C=C(C=C(C=3)C(F)(F)F)C(F)(F)F)OC(=O)NC2)=C1 FHSSJNHSAYDJHV-UHFFFAOYSA-N 0.000 description 1
- VEZFZDPMCIZCLQ-UHFFFAOYSA-N 9-[3,5-bis(trifluoromethyl)benzoyl]-5-phenyl-1-oxa-3,9-diazaspiro[5.5]undecan-2-one Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C(=O)N2CCC3(CC2)C(CNC(=O)O3)C=2C=CC=CC=2)=C1 VEZFZDPMCIZCLQ-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 206010066091 Bronchial Hyperreactivity Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 206010011971 Decreased interest Diseases 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- AHVYPIQETPWLSZ-UHFFFAOYSA-N N-methyl-pyrrolidine Natural products CN1CC=CC1 AHVYPIQETPWLSZ-UHFFFAOYSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 229940123821 Neurokinin 1 receptor antagonist Drugs 0.000 description 1
- 102000028517 Neuropeptide receptor Human genes 0.000 description 1
- 108070000018 Neuropeptide receptor Proteins 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000021957 Ocular injury Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- ZPHBZEQOLSRPAK-UHFFFAOYSA-N Phosphoramidon Natural products C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O ZPHBZEQOLSRPAK-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 208000012545 Psychophysiologic disease Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- XITRKVKEIBZFPG-UHFFFAOYSA-N [4-(2-amino-1-phenylethyl)-4-hydroxypiperidin-1-yl]-[3,5-bis(trifluoromethyl)phenyl]methanone Chemical compound C1CN(C(=O)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CCC1(O)C(CN)C1=CC=CC=C1 XITRKVKEIBZFPG-UHFFFAOYSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 230000036427 bronchial hyperreactivity Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006264 debenzylation reaction Methods 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000002895 emetic Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000008011 inorganic excipient Substances 0.000 description 1
- 229960004903 invert sugar Drugs 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 201000003152 motion sickness Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- PFPSZGPAQFBVHZ-UHFFFAOYSA-N n-(3-chlorophenyl)-2-[(4-phenyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)sulfanyl]acetamide Chemical compound ClC1=CC=CC(NC(=O)CSC=2N(C(C=3C=CN=CC=3)=NN=2)C=2C=CC=CC=2)=C1 PFPSZGPAQFBVHZ-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000008012 organic excipient Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- ZPHBZEQOLSRPAK-XLCYBJAPSA-N phosphoramidon Chemical compound N([C@@H](CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)P(O)(=O)O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O ZPHBZEQOLSRPAK-XLCYBJAPSA-N 0.000 description 1
- 108010072906 phosphoramidon Proteins 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 210000003594 spinal ganglia Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000002462 tachykinin receptor antagonist Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01111644 | 2001-05-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200308535B true ZA200308535B (en) | 2005-01-31 |
Family
ID=8177412
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200308535A ZA200308535B (en) | 2001-05-14 | 2003-10-31 | 1-Oxa-3,9-diaza-spiro[5,5]undecan-2-ones derivatives and its use as antagonist of the neurikinin receptor. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US6599900B2 (enExample) |
| EP (1) | EP1390372B1 (enExample) |
| JP (1) | JP4056887B2 (enExample) |
| KR (1) | KR100618063B1 (enExample) |
| CN (1) | CN1264847C (enExample) |
| AR (1) | AR033631A1 (enExample) |
| AT (1) | ATE401333T1 (enExample) |
| AU (1) | AU2002342238B2 (enExample) |
| BR (1) | BR0209604A (enExample) |
| CA (1) | CA2447329C (enExample) |
| DE (1) | DE60227657D1 (enExample) |
| DK (1) | DK1390372T3 (enExample) |
| ES (1) | ES2310206T3 (enExample) |
| MX (1) | MXPA03010321A (enExample) |
| PT (1) | PT1390372E (enExample) |
| WO (1) | WO2002092604A1 (enExample) |
| ZA (1) | ZA200308535B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007522160A (ja) * | 2004-02-10 | 2007-08-09 | エフ．ホフマン−ラ ロシュ アーゲー | ケモカインｃｃｒ５受容体モジュレーター |
| WO2006089674A2 (en) | 2005-02-25 | 2006-08-31 | F.Hoffmann-La Roche Ag | Tablets with improved drug substance dispersibility |
| CN101133064B (zh) * | 2005-03-03 | 2011-02-23 | 詹森药业有限公司 | 取代的氧杂-二氮杂-螺-[5.5]-十一烷酮衍生物及其作为神经激肽拮抗剂的应用 |
| ES2350647T3 (es) | 2005-03-08 | 2011-01-25 | Janssen Pharmaceutica Nv | Derivados de diaza-espiro-[4.4]-nonano como antagonistas de neuroquininas (nk1). |
| US7470684B2 (en) | 2007-01-03 | 2008-12-30 | Hoffmann-La Roche Inc. | Spiropiperidine derivatives as NK3 antagonists |
| WO2008090114A1 (en) | 2007-01-24 | 2008-07-31 | Glaxo Group Limited | Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-) |
| MX2009010503A (es) | 2007-03-29 | 2009-10-19 | Hoffmann La Roche | Compuestos heterociclicos antiviricos. |
| WO2017021805A1 (en) | 2015-07-31 | 2017-02-09 | Pfizer Inc. | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors |
| BR112019014688A2 (pt) | 2017-01-20 | 2020-02-18 | Pfizer Inc. | Derivados de carbamato de 1,1,1-trifluoro-3-hidroxipropan-2-il como inibidores de magl |
| JP2020506903A (ja) | 2017-01-23 | 2020-03-05 | ファイザー・インク | Ｍａｇｌ阻害薬としての複素環式スピロ化合物 |
| WO2020048827A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Aktiengesellschaft | 1, 3, 9-triazaspiro[5.5] undecan-2-one compounds |
| WO2020048826A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Aktiengesellschaft | 5-substituted 1-oxa-3,9-diazaspiro[5.5]undecan-2-one compounds |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2131021B (en) * | 1982-11-24 | 1985-12-18 | Erba Farmitalia | Antipsychotic benzoxazines |
| IL111960A (en) * | 1993-12-17 | 1999-12-22 | Merck & Co Inc | Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them |
| CA2233204A1 (en) * | 1995-09-29 | 1997-04-03 | Joseph A. Jakubowski | Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation |
-
2002
- 2002-05-06 DK DK02742943T patent/DK1390372T3/da active
- 2002-05-06 WO PCT/EP2002/004935 patent/WO2002092604A1/en not_active Ceased
- 2002-05-06 DE DE60227657T patent/DE60227657D1/de not_active Expired - Lifetime
- 2002-05-06 KR KR1020037014713A patent/KR100618063B1/ko not_active Expired - Fee Related
- 2002-05-06 EP EP02742943A patent/EP1390372B1/en not_active Expired - Lifetime
- 2002-05-06 AT AT02742943T patent/ATE401333T1/de not_active IP Right Cessation
- 2002-05-06 CA CA002447329A patent/CA2447329C/en not_active Expired - Fee Related
- 2002-05-06 MX MXPA03010321A patent/MXPA03010321A/es active IP Right Grant
- 2002-05-06 ES ES02742943T patent/ES2310206T3/es not_active Expired - Lifetime
- 2002-05-06 JP JP2002589488A patent/JP4056887B2/ja not_active Expired - Fee Related
- 2002-05-06 BR BR0209604-8A patent/BR0209604A/pt not_active IP Right Cessation
- 2002-05-06 PT PT02742943T patent/PT1390372E/pt unknown
- 2002-05-06 CN CNB028094735A patent/CN1264847C/zh not_active Expired - Fee Related
- 2002-05-06 AU AU2002342238A patent/AU2002342238B2/en not_active Ceased
- 2002-05-10 US US10/143,431 patent/US6599900B2/en not_active Expired - Fee Related
- 2002-05-10 AR ARP020101705A patent/AR033631A1/es unknown
-
2003
- 2003-10-31 ZA ZA200308535A patent/ZA200308535B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP4056887B2 (ja) | 2008-03-05 |
| DE60227657D1 (de) | 2008-08-28 |
| KR100618063B1 (ko) | 2006-08-30 |
| MXPA03010321A (es) | 2004-02-17 |
| WO2002092604A1 (en) | 2002-11-21 |
| EP1390372A1 (en) | 2004-02-25 |
| CN1264847C (zh) | 2006-07-19 |
| ES2310206T3 (es) | 2009-01-01 |
| EP1390372B1 (en) | 2008-07-16 |
| JP2004534758A (ja) | 2004-11-18 |
| US6599900B2 (en) | 2003-07-29 |
| BR0209604A (pt) | 2004-03-23 |
| ATE401333T1 (de) | 2008-08-15 |
| PT1390372E (pt) | 2008-08-25 |
| US20030004163A1 (en) | 2003-01-02 |
| CA2447329C (en) | 2009-07-28 |
| DK1390372T3 (da) | 2008-09-15 |
| KR20030094405A (ko) | 2003-12-11 |
| AU2002342238B2 (en) | 2007-01-25 |
| CN1507449A (zh) | 2004-06-23 |
| CA2447329A1 (en) | 2002-11-21 |
| AR033631A1 (es) | 2003-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1292596B1 (en) | 1,3,8-triaza-spiro¬4,5 decan-4-one derivatives as neurokinin receptor antagonists | |
| JP4445504B2 (ja) | Ｄｐｐ−ｉｖ阻害剤としてのヘキサヒドロピリドイソキノリン | |
| US5597826A (en) | Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist | |
| AU2001267513A1 (en) | 1,3,8-triaza-spiro'4,5!decan-4-one derivatives as neurokinin receptor antagonists | |
| PL190218B1 (pl) | Pochodna 5H-tiazolo[3,2-a]pirymidyny, sposób jej wytwarzania i zawierający ją lek oraz jej zastosowanie | |
| TW201105667A (en) | Dihydronaphthyridinyl and related compounds for use in treating ophthalmological disorders | |
| ZA200308535B (en) | 1-Oxa-3,9-diaza-spiro[5,5]undecan-2-ones derivatives and its use as antagonist of the neurikinin receptor. | |
| CA2326529C (en) | 2-(3,5-bis-trifluoromethyl-phenyl)-n-methyl-n-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide | |
| US20030130508A1 (en) | Heteroaromatic substituted amides with antagonistic activity to neurokinin 1 receptors | |
| DE69911580T2 (de) | Benzamidderivate als vasopressin-antagonisten | |
| AU2002342238A1 (en) | 1-oxa-3,9-diaza-spiro'5,5!undecan-2-ones derivatives and its use as antagonist of the neurikinin receptor | |
| CN105814044A (zh) | 作为tnf活性调节剂的四氢咪唑并吡啶衍生物 | |
| NZ530579A (en) | Highly selective NK-1 receptor (substance P) antagonists | |
| DK170670B1 (da) | Kondenserede diazepinoner, fremgangsmåde til deresfremstilling, lægemidler indeholdende en sådan diazepinon, samt anvendelse af sådanne diazepinoner til fremstilling af lægemidler | |
| JP2008521771A (ja) | 改良された抗精神病活性および抗不安症活性を有するイソキサゾリン−インドール誘導体 | |
| JP4781362B2 (ja) | ４級アンモニウム基を有するキヌクリジン化合物とその調製方法、およびアセチルコリン遮断剤としての用途 | |
| WO2000073313A1 (en) | New tricyclic amidine derivatives as inhibitors of nitric oxide synthase |